Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Guibaud

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
The Journal of Experimental Medicine|January 26, 2022
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisibGabriel Morin, Caroline Degrugillier-Chopinet, Marie Vincent, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2025
<i>PIK3CA</i> gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effectQuitterie Venot, Marina Firpion, Sophia Ladraa, et al.
Science Translational Medicine|October 6, 2021
Alpelisib administration reduced lymphatic malformations in a mouse model and in patientsFlorence Delestre, Quitterie Venot, Charles Bayard, et al.
JAMA Dermatology|September 15, 2021
Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS TrialAnnabel Maruani, Elsa Tavernier, Olivia Boccara, et al.
Trials|June 28, 2018
Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase designAnnabel Maruani, Olivia Boccara, Didier Bessis, et al.
Birth Defects Research|December 2, 2017
In utero ultrasound diagnosis of corpus callosum agenesis leading to the identification of orofaciodigital type 1 syndrome in female fetusesCaroline Alby, Lucile Boutaud, Maryse Bonnière, et al.
Prenatal Diagnosis|June 8, 2020
Ultrasound features of fetal toxoplasmosis: A contemporary multicenter survey in 88 fetusesCamille Codaccioni, Olivier Picone, Véronique Lambert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 25, 2024
Long-term effects of sirolimus treatment for slow-flow vascular malformations: Real-world evidence from the French observational multicentre SIROLO studyCécilia Maillet, Olivia Boccara, Stéphanie Mallet, et al.
Prenatal Diagnosis|May 13, 2023
Abnormalities of the corpus callosum. Can prenatal imaging predict the genetic status? Correlations between imaging phenotype and genotypeToan Nguyen, Solveig Heide, Lucie Guilbaud, et al.
Trials|December 19, 2019
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trialSophie Leducq, Agnès Caille, Sébastien Barbarot, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
The Journal of Experimental Medicine|January 26, 2022
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisibGabriel Morin, Caroline Degrugillier-Chopinet, Marie Vincent, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 2025
<i>PIK3CA</i> gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effectQuitterie Venot, Marina Firpion, Sophia Ladraa, et al.
Science Translational Medicine|October 6, 2021
Alpelisib administration reduced lymphatic malformations in a mouse model and in patientsFlorence Delestre, Quitterie Venot, Charles Bayard, et al.
JAMA Dermatology|September 15, 2021
Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS TrialAnnabel Maruani, Elsa Tavernier, Olivia Boccara, et al.
Trials|June 28, 2018
Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase designAnnabel Maruani, Olivia Boccara, Didier Bessis, et al.
Birth Defects Research|December 2, 2017
In utero ultrasound diagnosis of corpus callosum agenesis leading to the identification of orofaciodigital type 1 syndrome in female fetusesCaroline Alby, Lucile Boutaud, Maryse Bonnière, et al.
Prenatal Diagnosis|June 8, 2020
Ultrasound features of fetal toxoplasmosis: A contemporary multicenter survey in 88 fetusesCamille Codaccioni, Olivier Picone, Véronique Lambert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 25, 2024
Long-term effects of sirolimus treatment for slow-flow vascular malformations: Real-world evidence from the French observational multicentre SIROLO studyCécilia Maillet, Olivia Boccara, Stéphanie Mallet, et al.
Prenatal Diagnosis|May 13, 2023
Abnormalities of the corpus callosum. Can prenatal imaging predict the genetic status? Correlations between imaging phenotype and genotypeToan Nguyen, Solveig Heide, Lucie Guilbaud, et al.
Trials|December 19, 2019
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trialSophie Leducq, Agnès Caille, Sébastien Barbarot, et al.
Pageof 11